-+ 0.00%
-+ 0.00%
-+ 0.00%

Evaxion Publishes Q3 2026 Results and Strategy Update Transcript

PUBT·11/20/2026 12:00:31
Listen to the news
Evaxion Publishes Q3 2026 Results and Strategy Update Transcript
  • Evaxion is redirecting its own resources to oncology, prioritizing cancer vaccines while seeking partners for infectious disease assets.
  • The November 19, 2026, third-quarter results call featured CEO Helen Tayton-Martin, CSO/COO Birgitte Rono, CFO Thomas Schmidt and analysts.
  • Management expects to file the EVX-04 clinical trial application by year-end; expansion of EVX-01 beyond advanced melanoma will likely involve partnerships.
  • Cash runway now extends toward the end of 2027, supported by ATM proceeds; expected annual cash burn remains approximately $14 million.
  • Quarterly net loss totaled $3.5 million versus a $4.6 million year-earlier profit, reflecting no recognized revenue versus prior-year EVX-B3 licensing revenue.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief on November 19, 2026, and is solely responsible for the information contained therein.